ReviewStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Ultrahypofractionation of localized prostate cancer-an updated statement of the prostate cancer working group of the German Society of Radiation Oncology (DEGRO).
Review in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer (PCa) is the most frequently diagnosed malignancy among men in Germany. Radiation therapy is a standard treatment for localized PCa. Ultrahypofractionation (UHF) delivers high doses in fewer fractions, thus offering a time-efficient option compared to traditional standard fractionation lasting for 7-8 weeks. The German Society of Radiation Oncology (DEGRO) expert panel statement provides an updated evaluation of randomized trials with at least 5 years of follow-up.
methodsThe members of the DEGRO PCa working group performed a literature search for randomized trials of UHF for localized prostate cancer in March 2025. The analysis included phase III randomized trials with at least 5 years of follow-up: HYPO-RT-PC, PACE‑B, and a proton therapy trial.
resultsAll trials demonstrated noninferiority of UHF radiotherapy in maintaining disease control. The HYPO-RT-PC trial reported a 5‑year failure-free survival rate of 84% in both treatment groups and PACE‑B reported noninferiority with a 95.8% rate in the SBRT group compared to 94.6% in the control group. Acute urinary and bowel toxicities were more pronounced in UHF arms but resolved over time. Late urinary toxicity was significantly higher in SBRT patients (26.9% vs. 18.3%, p < 0.001, PACE-B). Proton SBRT showed slightly increased toxicity measured by sexual and urinary EPIC.
conclusionUltrahypofractionation represents an effective alternative to conventional fractionation in low- to intermediate-risk PCa with similar oncologic outcomes. However, physicians should inform their patients-particularly those with suboptimal urinary function-about an increased risk for GU toxicity.
Indexed as
Identifiers
42432214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.